NLS COVID-19

A small trial shows that the anticancer drug bevacizumab is extremely effective in reducing severe COVID-19 symptoms. The results have been published in Nature Communications and the Novo Nordisk Foundation has reported about the findings. “The results are very promising. We hope that this initial trial can pave the way for larger randomized controlled trials […]

One dose of AstraZeneca’s COVID-19 vaccine generates equal amounts of antibodies as two doses of Pfizer/BioNTech’s mRNA vaccine if the person has previously had COVID-19. These are the findings from a co-study of the COMMUNITY study at Danderyd’s Hospital that investigates immunity after COVID-19. During the spring of 2020 samples from 2,149 co-workers at Danderyd’s […]

Capitainer has announced that its home self-sampling kit proves 97% effective for clinical mass-testing of COVID-19 vaccine efficacy. In a recent Swedish large scale population study, 97% of the samples self-collected and returned to the lab by private individuals met the official quality standard for accurate analysis resulting in clinical diagnosis, states the company in […]

Researchers at Karolinska Institutet and the Public Health Agency of Sweden have shown that although babies born of test-positive mothers are more likely to be born early, extremely few were infected with COVID-19. The study, published in the journal JAMA, supports the Swedish recommendation not to separate mother and baby after delivery, states the researchers […]

Valneva SE has initiated a Phase 3 clinical trial for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. The Phase 3 trial “Cov-Compare”, (VLA2001-301), will compare Valneva’s SARS-CoV-2 vaccine candidate, VLA2001, against AstraZeneca’s conditionally approved vaccine, Vaxzevria, in a comparative immunogenicity trial, states Valneva in a press release. Cov-Compare Approximately 4,000 participants will receive two doses […]

The company launched a home testing kit in March that detects antibodies against SARS-CoV-2 and has now been given an assignment by the Swedish Public Health Agency. “This is amazing news,” says Julia Wigren Byström, CEO of Xerum. “We will be responsible for the distribution and analysis of our self-sampling kits as part of a […]